In Vitro Diagnostics – IVD News

NEW YORK (GenomeWeb) Mar 26, 2019 – Vela Diagnostics has submitted a next-generation sequencing (NGS) assay that detects HIV-1 drug resistance mutations (DRMs) to the US Food and Drug Administration (FDA), the company announced today. The Sentosa SQ HIV Genotyping Assay can be used on plasma samples from patients with HIV-1 infection to detect HIV-1…

Menarini Diagnostics to distribute Unyvero Platform and application cartridges in numerous European countries Menarini Diagnostics to deploy its commercial team for the marketing of Unyvero Platform across Europe Partnership to be launched at ECCMID 2019 in Amsterdam Amsterdam, the Netherlands, and Holzgerlingen, Germany, March 26, 2019, 08:00 am CET – Curetis N.V. (the “Company” and,…

Berlin (Germany) and San Diego, CA (U.S.A.), March 15, 2019 – Representatives Donald Payne, Jr. (D-NJ) and Kenny Marchant (R-TX) today introduced the ”Donald Payne Sr. Colorectal Cancer Detection Act” to the United States House of Representatives in Washington D.C. This House Bill aims to provide payment and coverage under the Medicare program for FDA-approved…

February 18, 2019, 22:00 CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) have entered into a strategic licensing agreement for ARESdb and AREStools in…

Amsterdam, the Netherlands, and Holzgerlingen, Germany, February 04, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that Beijing Clear Biotech (BCB) has filed for regulatory approval of the Unyvero A50 HPN Application Cartridge for pneumonia with the Chinese National…

Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 30, 2019; published at 08:00 a.m. CET — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its partner for the commercialization of Unyvero in the ASEAN region, Acumen Research Laboratories Pte Ltd. (Acumen), has received first…

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency Initiates set-up of R&D and service laboratory in Vienna Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The Netherlands; January 08, 2019; published at 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level…

> Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform > Collaboration leverages Ares Genetics’ antibiotic resistance database ARESdb > Short-term focus on repurposing existing antibiotics to treat infections with multi drug resistant pathogens Vienna, Austria, Holzgerlingen, Germany and Amsterdam, The Netherlands; December 18, 2018; published at 08:00 am CET – Curetis N.V. (the…

NEW YORK (GenomeWeb) – Curetis announced today that it has extended an exclusive distribution agreement with Beijing Clear Biotech (BCB), expanding it from five years to eight years following the first Chinese regulatory approval. The strategic collaboration covers distribution of the Curetis Unyvero A50 platform and assay cartridges in China. The amendment to the original…

ARESupa test aims at broad detection of microbial infections employing next-generation sequencing and artificial intelligence Curetis explores venture capital (VC) funding for Ares Genetics while assessing all strategic and tactical financing options for growth of Unyvero core business Amsterdam, the Netherlands, Holzgerlingen, Germany, and Vienna, Austria, September 04, 2018, 01:00 am EST – Curetis N.V.…